Recent CDC data show that that wastewater SARS-CoV-2 detections are high and that LP.8.1 and related strains XFG and NB.1.8.1 ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

丙酸血症是一种罕见的“中毒型”有机酸血症。在日本，通过筛查发现的PA发病率约为每45,000名活产婴儿中就有1例。它具有多系统并发症，包括神经系统表现、心肌病、心律失常、生长迟缓、复发性胰腺炎、骨髓抑制和对感染的高度易感性。其特征是反复发生的、危及生命的代谢失代偿事件（MDEs），MDEs是导致死亡率和长期不可逆神经认知缺陷的主要因素。目前的治疗方法不能解决根本的酶缺陷，主要包括饮食蛋白质限制以减 ...

CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its ...

Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced positive ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

Moderna (MRNA) announced “positive” preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of ...

CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 ...

Moderna MRNA and Merck MRK announced new data for individualized neoantigen therapy mRNA-4157 on Monday at the annual meeting of the American Society of Clinical Oncology that was consistent with our ...

No sooner did Moderna (MRNA) and Merck & Co. (MRK) announce additional positive data for their cancer vaccine candidate, a messenger RNA (mRNA)-based individualized neoantigen therapy (INT), than ...

Clinical data demonstrate that Moderna’s proprietary vaccine technology has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical experience across ...